Lymphoma & Plasma Cell Disorders

Myeloma risk score has treatment-planning potential

March 12, 2019

Myeloma therapies raise cardiovascular risks

March 1, 2019

Selinexor hits FDA stumbling block

February 26, 2019

Similar results for once- or twice-weekly carfilzomib in MM

February 23, 2019

Haplo-HCT shows viability in DLBCL

February 21, 2019

Lymphoma & Plasma Cell Disorders

Researchers characterize new subtype of high-grade DLBCL

February 17, 2019

Lymphoma & Plasma Cell Disorders

CAR T-cell therapies difficult to compare

February 16, 2019

Lymphoma & Plasma Cell Disorders

Advances in CAR T-Cell Therapies (FULL)

February 11, 2019

The Use of Immuno-Oncology Treatments in the VA (FULL)

February 4, 2019

10 Important VA Studies You Might Have Missed at ASH

December 14, 2018

2018: A banner year for hematology drug approvals

December 5, 2018

In IDH-mutated AML, first-line IDH inhibitors plus chemo may boost remission

December 5, 2018

TOURMALINE-MM3: Ixazomib improves PFS after myeloma transplant

December 2, 2018

JULIET: CAR T cells go the distance in r/r DLBCL

December 2, 2018

Lymphoma & Plasma Cell Disorders

Beat AML trial delivers genomic results in 7 days

December 2, 2018